38P Assessment of lipidomic profile in endocrine receptor-positive (ER+) MBC patients treated with CDK 4/6 inhibitors (CDKi) and endocrine therapy (ET)

DOI: 10.1016/j.esmoop.2023.101262 Publication Date: 2023-05-15T10:28:29Z